ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...

Barré syndrome market is poised for substantial growth, fueled by advancements in treatment options, including intravenous immunoglobulin (IVIg), plasmapheresis, and emerging immunotherapies.

Background Acute upper gastrointestinal bleeding (AUGIB) is a common medical emergency with evolving demographics and ...

Vadodara: A young man who once lay motionless on a ventilator, trapped between life and death, is now walking again — the ...

A large study of US adults 65 and older enrolled in Medicare finds that the risk of Guillain-Barre syndrome (GBS)—a rare ...

The adjusted incident rate ratio (IRR) for GBS post-RSV disease was 2.11, reflecting a slightly more than double risk. The ...

Relly Ladner clutched her shin on the soccer field. At 17 years old, and training with her team, she was suddenly feeling a ...

Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome (GBS) and Geographic Atrophy ...

The residents of Gaza City are not only corralled by Israel’s siege and bombing, but also by infections from overflowing ...

Background Acute upper gastrointestinal bleeding (AUGIB) is a common medical emergency globally. We report endoscopic management of AUGIB in a large UK multicentre study. Methods A prospective audit ...